Search
Close this search box.

NIIMBL Awards $600K for 7 eXperience Programs in 2025

NIIMBL eXperience logo

NIIMBL is pleased to announce it has awarded $600K to launch seven NIIMBL eXperience programs in regions throughout the United States during the summer of 2025. Each location will host a week-long program, designed to foster diversity within the biopharmaceutical industry and introduce first- and second-year college students to new career possibilities.

NIIMBL collaborates on review of vaccine process technology developments

Vaccine and vile. NIIMBL publishes 10-year lookback at vaccine process technology.

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has published “Vaccine process technology—a decade of progress” in Biotechnology and Bioengineering. The paper serves as an update to a 2012 review titled “Vaccine process technology” authored by NIIMBL Executive Director Barry Buckland and explores transformations in vaccine development over the past decade.

NIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing Projects

NEWARK, Del., April 9, 2024 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce approximately $10M in planned project activities through the Institute’s Project Call 7.1 for eight new technology and workforce development projects that will help address key opportunities for innovation in biopharmaceutical manufacturing.

NIIMBL Is Now Accepting Applications for the 2024 NIIMBL eXperience Cohort

NIIMBL eXperience logo

Newark, Del., October 17, 2023 – The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has awarded approximately $500k in funding to launch the 2024 NIIMBL eXperience program in five locations across the United States. The application period is now open for the following locations: Albany College of Pharmacy and Health Sciences (ACPHS)- New York, Biomanufacturing Training Center at North Carolina State University, Thomas Jefferson University- Pennsylvania, Santa Clara University- California, and the…

NIIMBL Launches Viral Vector Program to Improve Access to AAV Gene Therapy

NEWARK, Del., October 10, 2023 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) officially launches the Viral Vectors NIIMBL-led Program focused on developing and making broadly available robust, economically viable, shared manufacturing process and analytical platforms for Adeno-Associated Virus (AAV) gene therapy vectors. NIIMBL has committed to this effort with an ultimate vision to provide access to high quality viral vectors capable of serving the full spectrum of patient need, from prevalent indications to ultra-rare diseases, without cost or…

NIIMBL awards $370K for 5 eXperience programs in 2024

NIIMBL is pleased to announce it has awarded $370K to launch five NIIMBL eXperience programs next summer. These host locations represent distinct regions across the country. Each location will host a week-long program, designed to introduce Black, Latinx, and Indigenous college students to career possibilities in the biopharmaceutical industry. The 2024 NIIMBL eXperience host locations are…

NIIMBL Announces RFI for Next-Generation Sequencing Method Development Study

NEWARK, Del., August 10, 2023 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce a Request for Information (RFI) related to a planned method development study, focused on the development and optimization of Next-Generation Sequencing (NGS) methods for extended characterization of Adeno-Associated Virus (AAV) gene therapy…